Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Truist Financial Corp

Truist Financial Corp lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 360,175 shares of the biopharmaceutical company's stock after selling 9,560 shares during the period. Truist Financial Corp's holdings in Gilead Sciences were worth $40,358,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of GILD. Smallwood Wealth Investment Management LLC purchased a new stake in Gilead Sciences during the 1st quarter valued at about $25,000. Goodman Advisory Group LLC purchased a new position in shares of Gilead Sciences during the 1st quarter worth $29,000. Annis Gardner Whiting Capital Advisors LLC raised its holdings in shares of Gilead Sciences by 158.8% during the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after acquiring an additional 216 shares during the period. Lee Danner & Bass Inc. purchased a new position in shares of Gilead Sciences during the 4th quarter worth $41,000. Finally, Investment Research & Advisory Group Inc. raised its holdings in shares of Gilead Sciences by 33.3% during the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 100 shares during the period. Hedge funds and other institutional investors own 83.67% of the company's stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction on Monday, June 30th. The shares were sold at an average price of $110.45, for a total value of $1,104,500.00. Following the transaction, the chief executive officer directly owned 615,725 shares in the company, valued at approximately $68,006,826.25. The trade was a 1.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction on Monday, June 16th. The shares were sold at an average price of $110.17, for a total transaction of $330,510.00. Following the completion of the transaction, the insider owned 120,168 shares in the company, valued at approximately $13,238,908.56. This represents a 2.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 58,500 shares of company stock valued at $6,340,745 over the last ninety days. Insiders own 0.27% of the company's stock.

Gilead Sciences Stock Up 1.1%

Shares of Gilead Sciences stock traded up $1.30 during trading on Thursday, hitting $114.54. 6,096,566 shares of the stock were exchanged, compared to its average volume of 7,692,111. The stock has a market cap of $142.48 billion, a price-to-earnings ratio of 24.11, a price-to-earnings-growth ratio of 0.72 and a beta of 0.29. The firm's 50-day moving average price is $107.40 and its 200 day moving average price is $104.35. Gilead Sciences, Inc. has a 12-month low of $67.65 and a 12-month high of $119.96. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The firm had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. During the same period in the previous year, the company earned ($1.32) earnings per share. Gilead Sciences's quarterly revenue was down .3% compared to the same quarter last year. As a group, analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were given a $0.79 dividend. The ex-dividend date of this dividend was Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a yield of 2.76%. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Analyst Ratings Changes

Several analysts have recently weighed in on GILD shares. Oppenheimer dropped their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, April 25th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Cantor Fitzgerald began coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price target for the company. JPMorgan Chase & Co. lifted their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Finally, Morgan Stanley lifted their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Nine research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $111.38.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.